Philadelphia biopharm company partners with Chinese firm to advance cancer therapy

Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate. That experimental therapy, called onapristone ER, is being evaluated in mid-stage clinical testing in patients with certain types of ovarian and endometrial cancers. Context plans to conduct mid-stage clinical testing of onapristone ER in patients with breast cancer later this year. Financial…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news